<DOC>
	<DOCNO>NCT00414765</DOCNO>
	<brief_summary>This study evaluate pharmacokinetics aldesleukin patient metastatic renal cell cancer metastatic melanoma</brief_summary>
	<brief_title>Aldesleukin Patients With Metastatic Renal Cell Carcinoma Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Inclusion criterion : Performance Status Eastern Cooperative Oncology Group : 0 1 Adequate organ function Exclusion criterion : Pregnancy lactation Prior treatment aldesleukin Organ transplant Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Metastatic Renal Cell Carcinoma</keyword>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>Aldesleukin</keyword>
	<keyword>IL-2</keyword>
</DOC>